Evonik Industries AG (ETR:EVK)
Germany · Delayed Price · Currency is EUR 16.30
-1.17 (-6.70%)
Aug 1, 2025, 5:35 PM CET
Theseus Pharmaceuticals Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 424 | 222 | -465 | 540 | 746 | 465 | Upgrade |
Depreciation & Amortization | 1,021 | 1,036 | 1,366 | 1,113 | 1,021 | 993 | Upgrade |
Other Amortization | 2 | 2 | 2 | 2 | 2 | - | Upgrade |
Loss (Gain) From Sale of Assets | 45 | 22 | -1 | -50 | 43 | -10 | Upgrade |
Asset Writedown & Restructuring Costs | 79 | 79 | 473 | 453 | 50 | 25 | Upgrade |
Loss (Gain) on Equity Investments | -18 | -21 | -10 | -12 | -8 | -15 | Upgrade |
Other Operating Activities | 201 | 169 | 15 | 247 | 138 | 298 | Upgrade |
Change in Accounts Receivable | 77 | 21 | 105 | 42 | -449 | 54 | Upgrade |
Change in Inventory | -178 | -297 | 310 | -270 | -675 | 70 | Upgrade |
Change in Accounts Payable | -219 | 74 | -157 | -257 | 680 | -30 | Upgrade |
Change in Other Net Operating Assets | -109 | 406 | -44 | -158 | 267 | -114 | Upgrade |
Operating Cash Flow | 1,325 | 1,713 | 1,594 | 1,650 | 1,815 | 1,727 | Upgrade |
Operating Cash Flow Growth | -36.05% | 7.46% | -3.39% | -9.09% | 5.10% | 30.73% | Upgrade |
Capital Expenditures | -812 | -840 | -793 | -865 | -886 | -956 | Upgrade |
Sale of Property, Plant & Equipment | 10 | 21 | 15 | 5 | 9 | 45 | Upgrade |
Cash Acquisitions | - | -15 | -76 | -1 | -70 | -451 | Upgrade |
Divestitures | 10 | 3 | 11 | 97 | -145 | 20 | Upgrade |
Investment in Securities | 137 | 131 | 158 | -29 | 10 | 742 | Upgrade |
Other Investing Activities | -109 | 37 | 32 | 16 | 12 | 30 | Upgrade |
Investing Cash Flow | -764 | -663 | -653 | -777 | -1,070 | -570 | Upgrade |
Long-Term Debt Issued | - | 708 | 716 | 1,649 | 655 | 1,039 | Upgrade |
Long-Term Debt Repaid | - | -1,354 | -893 | -1,577 | -948 | -2,156 | Upgrade |
Net Debt Issued (Repaid) | -9 | -646 | -177 | 72 | -293 | -1,117 | Upgrade |
Issuance of Common Stock | 1 | 9 | 12 | 12 | 12 | 12 | Upgrade |
Repurchase of Common Stock | -1 | -12 | -16 | -16 | -15 | -16 | Upgrade |
Common Dividends Paid | -545 | -545 | -545 | -545 | -536 | -536 | Upgrade |
Other Financing Activities | -124 | -136 | -97 | -195 | -24 | -77 | Upgrade |
Financing Cash Flow | -678 | -1,330 | -823 | -672 | -856 | -1,734 | Upgrade |
Foreign Exchange Rate Adjustments | -25 | -8 | -14 | -12 | 4 | -25 | Upgrade |
Net Cash Flow | -142 | -288 | 104 | 189 | -107 | -602 | Upgrade |
Free Cash Flow | 513 | 873 | 801 | 785 | 929 | 771 | Upgrade |
Free Cash Flow Growth | -61.37% | 8.99% | 2.04% | -15.50% | 20.49% | 74.83% | Upgrade |
Free Cash Flow Margin | 3.49% | 5.76% | 5.25% | 4.25% | 6.21% | 6.32% | Upgrade |
Free Cash Flow Per Share | 1.11 | 1.87 | 1.72 | 1.69 | 1.99 | 1.66 | Upgrade |
Cash Interest Paid | 109 | 109 | 99 | 73 | 94 | 77 | Upgrade |
Cash Income Tax Paid | 213 | 213 | 232 | 174 | 308 | 83 | Upgrade |
Levered Free Cash Flow | 1,654 | 705.15 | 1,118 | 395.13 | 770.14 | 596.2 | Upgrade |
Unlevered Free Cash Flow | 1,787 | 837.65 | 1,271 | 471.38 | 850.77 | 703.08 | Upgrade |
Change in Net Working Capital | -923 | -107 | -306 | 650 | 84 | -131 | Upgrade |
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.